We found SOX6 in both TCGA poor versus good and intermediate versus good risk subgroup comparisons and SOX5, SOX15 and SOX18 in both the TARGET standard versus low risk and TCGA poor versus good risk subgroup comparisons; however, only SOX18 has previously been implicated in reduced disease-free and OS in AML patients [46]. This evidence concerns the gene SOX15 and acute myeloid leukemia.